Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: A prospective observational study

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Yang, Kuang Yao ^a,b   Liu, Kuan Ting ^b,c   Chen, Yu Chun ^b,d   Chen, Chun Sheng ^a   Lee, Yu Chin ^a,b   Perng, Reury Perng ^a,b   Feng, Jia Yih ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SOLUBLE VASCULOTROPIN RECEPTOR 1; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; VASCULOTROPIN A;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DYSFUNCTION; MALE; METABOLIC ACIDOSIS; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; SURVIVOR; BLOOD; INTENSIVE CARE UNIT; PREDICTIVE VALUE; PROGNOSIS; STATISTICS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SHOCK, SEPTIC; TREATMENT OUTCOME; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 78650989117     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9412     Document Type: Article

References (32)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
2. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
3. Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, Schein R, Summer W, Wright P, Walley KR. Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 2000, 28:3405-3411. 10.1097/00003246-200010000-00005, 11057793.
4. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, . CUB-Réa Network Current epidemiology of septic shock: the CUB-Réa Network. Am J Respir Crit Care Med 2003, 168:165-172. 10.1164/rccm.2201087, 12851245, CUB-Réa Network.
5. Christaki E, Opal SM. Is the mortality rate for septic shock really decreasing?. Curr Opin Crit Care 2008, 14:580-586. 10.1097/MCC.0b013e32830f1e25, 18787453.
6. Bastarache JA, Ware LB, Bernard GR. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 2006, 27:365-376. 10.1055/s-2006-948290, 16909370.
7. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992, 3:211-220. 275520, 1550962.
8. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77:527-543. 10.1007/s001099900019, 10494799.
9. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985. 10.1126/science.6823562, 6823562.
10. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309. 10.1126/science.2479986, 2479986.
11. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255:989-991. 10.1126/science.1312256, 1312256.
12. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992, 187:1579-1586. 10.1016/0006-291X(92)90483-2, 1417831.
13. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996, 226:324-328. 10.1006/bbrc.1996.1355, 8806634.
14. Pickkers P, Sprong T, Eijk L, Hoeven H, Smits P, Deuren M. Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. Shock 2005, 24:508-512. 10.1097/01.shk.0000190827.36406.6e, 16317379.
15. van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoepelman AI, Geelen SP. Plasma vascular endothelial growth factor in severe sepsis. Shock 2005, 23:35-38. 10.1097/01.shk.0000150728.91155.41, 15614129.
16. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006, 203:1447-1458. 10.1084/jem.20060375, 2118329, 16702604.
17. Ebihara I, Hirayama K, Kaneko S, Nagai M, Ogawa Y, Fujita S, Usui J, Mase K, Yamagata K, Kobayashi M. Vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in septic shock patients treated with direct hemoperfusion with a polymyxin B-immobilized fiber column. Ther Apher Dial 2008, 12:285-291. 10.1111/j.1744-9987.2008.00589.x, 18789115.
18. Marshall BC, Xu QP, Rao NV, Brown BR, Hoidal JR. Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha. J Biol Chem 1992, 267:11462-11469.
19. Abraham E, Gyetko MR, Kuhn K, Arcaroli J, Strassheim D, Park JS, Shetty S, Idell S. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003, 170:5644-5651.
20. Reuning U, Sperl S, Kopitz C, Kessler H, Krüger A, Schmitt M, Magdolen V. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003, 9:1529-1543. 10.2174/1381612033454612, 12871066.
21. Behzadian MA, Windsor LJ, Ghaly N, Liou G, Tsai NT, Caldwell RB. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003, 17:752-754.
22. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, . American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754. American Thoracic Society.
23. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. 10.1164/rccm.200405-644ST, 15699079, American Thoracic Society; Infectious Diseases Society of America.
24. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, . Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.
25. Karlsson S, Pettilä V, Tenhunen J, Lund V, Hovilehto S, Ruokonen E, . Finnsepsis Study Group Vascular endothelial growth factor in severe sepsis and septic shock. Anesth Analg 2008, 106:1820-1826. 10.1213/ane.0b013e31816a643f, 18499616, Finnsepsis Study Group.
26. Vidal F, Aragonés J, Alfranca A, de Landázuri MO. Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1. Blood 2000, 95:3387-3395.
27. Plaschke K, Staub J, Ernst E, Marti HH. VEGF overexpression improves mice cognitive abilities after unilateral common carotid artery occlusion. Exp Neurol 2008, 214:285-292. 10.1016/j.expneurol.2008.08.014, 18822285.
28. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001, 33:409-420. 10.1016/S1357-2725(01)00026-7, 11312109.
29. Cao D, Mizukami IF, Garni-Wagner BA, Kindzelskii AL, Todd RF, Boxer LA, Petty HR. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. J Immunol 1995, 154:1817-1829.
30. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004, 103:955-962. 10.1182/blood-2003-07-2214, 14525763.
31. Philippé J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 1991, 65:291-295.
32. Robbie LA, Dummer S, Booth NA, Adey GD, Bennett B. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. Br J Haematol 2000, 109:342-348. 10.1046/j.1365-2141.2000.02057.x, 10848822.